Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers
- PMID: 22502693
- DOI: 10.7314/apjcp.2012.13.1.319
Feasibility of shrinking field radiation therapy through 18F-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers
Abstract
Objective: To explore the feasibility of shrinking field technique after 40 Gy radiation through 18F-FDG PET/ CT during treatment for patients with stage III non-small cell lung cancer (NSCLC).
Methods: In 66 consecutive patients with local-advanced NSCLC, 18F-FDG PET/CT scanning was performed prior to treatment and repeated after 40 Gy. Conventionally fractionated IMRT or CRT plans to a median total dose of 66 Gy (range, 60-78 Gy) were generated. The target volumes were delineated in composite images of CT and PET. Plan 1 was designed for 40 Gy to the initial planning target volume (PTV) with a subsequent 20-28 Gy-boost to the shrunken PTV. Plan 2 was delivering the same dose to the initial PTV without shrinking field. Accumulated doses of normal tissues were calculated using deformable image registration during the treatment course.
Results: The median GTV and PTV reduction were 35% and 30% after 40 Gy treatment. Target volume reduction was correlated with chemotherapy and sex. In plan 2, delivering the same dose to the initial PTV could have only been achieved in 10 (15.2%) patients. Significant differences (p<0.05) were observed regarding doses to the lung, spinal cord, esophagus and heart.
Conclusions: Radiotherapy adaptive to tumor shrinkage determined by repeated 18F-FDG PET/CT after 40 Gy during treatment course might be feasible to spare more normal tissues, and has the potential to allow dose escalation and increased local control.
Similar articles
-
A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.Technol Cancer Res Treat. 2013 Jun;12(3):251-7. doi: 10.7785/tcrt.2012.500310. Epub 2012 Dec 26. Technol Cancer Res Treat. 2013. PMID: 23289475
-
Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?Radiother Oncol. 2008 Sep;88(3):335-41. doi: 10.1016/j.radonc.2008.05.004. Epub 2008 May 29. Radiother Oncol. 2008. PMID: 18514339
-
FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.Radiat Oncol. 2018 Oct 23;13(1):208. doi: 10.1186/s13014-018-1147-2. Radiat Oncol. 2018. PMID: 30352608 Free PMC article. Clinical Trial.
-
Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer.Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):709-19. doi: 10.1016/j.ijrobp.2006.09.046. Epub 2006 Dec 29. Int J Radiat Oncol Biol Phys. 2007. PMID: 17197120 Review.
-
Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC).Lung Cancer. 2007 Aug;57(2):125-34. doi: 10.1016/j.lungcan.2007.03.020. Epub 2007 May 2. Lung Cancer. 2007. PMID: 17478008 Review.
Cited by
-
Geometric and dosimetric accuracy of deformable image registration between average-intensity images for 4DCT-based adaptive radiotherapy for non-small cell lung cancer.J Appl Clin Med Phys. 2021 Aug;22(8):156-167. doi: 10.1002/acm2.13341. Epub 2021 Jul 26. J Appl Clin Med Phys. 2021. PMID: 34310827 Free PMC article.
-
Adaptive radiotherapy in lung cancer: dosimetric benefits and clinical outcome.Br J Radiol. 2014 Jun;87(1038):20130643. doi: 10.1259/bjr.20130643. Epub 2014 Mar 17. Br J Radiol. 2014. PMID: 24628269 Free PMC article.
-
In 18F-positron emission tomography/computed tomography-guided precision radiotherapy for centrally located non-small cell lung cancer, tumor related atelectasis is a prognostic factor of survival.Front Oncol. 2022 Jul 28;12:898233. doi: 10.3389/fonc.2022.898233. eCollection 2022. Front Oncol. 2022. PMID: 35965530 Free PMC article.
-
A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer.Oncotarget. 2018 Jan 3;9(15):12443-12451. doi: 10.18632/oncotarget.23849. eCollection 2018 Feb 23. Oncotarget. 2018. PMID: 29552324 Free PMC article.
-
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer.J Clin Oncol. 2024 Nov 20;42(33):3935-3946. doi: 10.1200/JCO.24.00022. Epub 2024 Oct 4. J Clin Oncol. 2024. PMID: 39365957 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials